Moreover, clinical research shows that Chm-1-specific allorestricted T-cell receptor (TCR) transgenic T cells home to bone marrow metastases and may cause partial disease regression without graft versus host disease (GvHD) in ES patients, indicating the need for future clinical trials [45]. This evidence concerns the gene CNMD and graft versus host disease.